A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.

Abstract

BACKGROUND Effective and safe products are needed for long-term management of scalp psoriasis. This study investigated the long-term safety and efficacy of a two-compound formulation (calcipotriol 50 microg/g plus betamethasone dipropionate 0.5 mg/g) for scalp psoriasis. METHODS In this 52-week, international, double-blind study, 869 patients with moderate-to-severe scalp psoriasis were randomized to either a two-compound scalp formulation (n = 429) or calcipotriol (n = 440). RESULTS Adverse drug reactions were less frequent in the two-compound group compared with the calcipotriol group (17.2 vs. 29.5%; p < 0.001). Incidences of adverse events possibly associated with long-term corticosteroid use were low in both the two-compound (2.6%) and the calcipotriol (3.0%) groups. Disease was satisfactorily controlled in 92.3% of visits in the two-compound group versus 80.0% in the calcipotriol group (p < 0.001). CONCLUSION The two-compound scalp formulation demonstrated a high level of safety and efficacy in long-term management of scalp psoriasis.

DOI: 10.1159/000155642

7 Figures and Tables

0204060200920102011201220132014201520162017
Citations per Year

158 Citations

Semantic Scholar estimates that this publication has 158 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Luger2008ASO, title={A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.}, author={Thomas Luger and Frederic Cambazard and Frederik Gr\onh\oj Larsen and Marc Bourcier and Girish Gupta and Fabrice Clonier and P Kidson and Neil H. Shear}, journal={Dermatology}, year={2008}, volume={217 4}, pages={321-8} }